Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN HYDROCHLORIDE.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs CIPROFLOXACIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
400 mg intravenously every 8-12 hours over 60 minutes.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic